tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

EW · Q2 2025 Earnings

Edwards Lifesciences

Reported July 24, 2025

30-second summary

Edwards raised full-year sales guidance to 9-10% (from 8-10%) and pulled adjusted EPS to the high end of the $2.40–$2.50 range on the back of Q2 revenue of $1.53B (+11.9% YoY), TAVR growth of 8.9%, and TMTT growth of 61.9%. Management's tone shifted from defending a TAVR-centric narrative to framing Edwards as uniquely positioned across repair and replacement in transcatheter mitral/tricuspid, with explicit commitments to 50-100bps of annual EBIT margin expansion starting 2026. The print validates the multi-modality portfolio thesis earlier than the Street modeled.

Headline numbers

EPS

Q2 FY2025

$0.67

Revenue

Q2 FY2025

$1.53B

+11.9% YoY

Gross margin

Q2 FY2025

77.5%

Operating margin

Q2 FY2025

26.8%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$1.53B+11.9%
EPS$0.67—
Gross margin77.5%—
Operating margin26.8%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Transcatheter Aortic Valve Replacement (TAVR)$1.131B+8.9%
Transcatheter Mitral and Tricuspid Therapies (TMTT)$0.134B+61.9%
Surgical Structural Heart$0.267B+7.7%
TAVR Sales Growth (Constant Currency)7.8%—
TMTT Sales Growth (Adjusted)57.1%—

Other KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
United States$0.89B+10.3%
Europe$0.378B+13.8%
Japan$0.095B+10.2%
Rest of World$0.169B+17.1%
Adjusted Operating Margin28.2%—
SG&A Expenses as % of Sales32.8%—
R&D Expenses as % of Sales18.0%—

Management tone

This is the first Tapebrief on EW, so the multi-quarter arc will build from here. The shifts below are framed against management's posture as captured in the source materials.

The most consequential change is how Edwards now positions TMTT. The framing has moved to a uniquely positioned, comprehensive repair-and-replacement portfolio, anchored by CEO Bernard Zovighian's statement that "our vision for TMTT has developed into a growth portfolio of groundbreaking trans-catheter repair and replacement technologies." Zovighian further described Edwards as "increasingly distinguished by our balanced portfolio of leading therapies across aortic, mitral and tricuspid which will position us for leadership for many years to come." That is a declarative claim of durable competitive advantage. With Pascal, Evoque, and Sapien M3 (now CE-marked) in the bag, management is signaling the competitive moat is wide enough to start anchoring valuation off.

TAVR's framing has also leaned more positive. Management describes "renewed focus on TAVR" and says "this new data set has just reprioritized these patients" in real time. The guide raise to 6-7% underlying growth from 5-7% is the concrete signal — and the tonal layer is that EARLY TAVR data is being credited as a near-term catalyst. The combination of asymptomatic indication approvals and a potential reopened US NCD is now described as a "multi-year growth opportunity."

Management's confidence in execution has hit a level unusual for this company. Zovighian's "We are the only company having this kind of bold strategy, a very unique innovation process. And we are executing in a very flawless fashion" is the kind of superlative Edwards has historically avoided. Paired with the explicit forward commitment to "50 to 100 basis points of EBIT margin on a constant currency basis increase starting in 2026," management has moved from defending the post-spin operating model to promoting it.

On competitive risk, the tone is didactic rather than defensive. Larry Wood's response on the Boston Scientific exit (see Q&A) frames pricing power as evidence-backed rather than positioning-dependent. This is a confidence inflection on the durability of TAVR ASPs.

The residual hedges are worth flagging: tariffs ("any modifications could have a material impact"), the Sapien M3 US approval slipping to 1H 2026, JenaValve close timing in Q3, and Japan share recapture explicitly acknowledged as uncertain. Management is bullish on the portfolio but has not airbrushed the operational risks.

Recurring themes management leaned on this quarter:

Early TAVR data catalyzing clinical re-engagement and mindshare shift in real timeTMTT as sole-provider, multi-modality portfolio (Pascal, Evoque, Sapien M3) with durable competitive moatNCD/guideline reopening as phased multi-year volume unlock (asymptomatic coverage + operator/facility simplification)Structural heart as balanced, synergistic growth engine replacing TAVR-centric narrativeEvidence-based pricing resilience vs. competitor exit and price-point risk2026+ operating leverage through scale, Genovalve accretion, and tariff normalization

Risks management surfaced:

Tariffs: 'impact from tariffs that are in effect or have been announced to date' and 'any modifications to such tariffs or any new tariffs could have a material impact'FX headwinds: 'FX rates negatively impacted our second quarter gross profit margin by 60 basis points'Genovalve integration and timing risk: 'we are reaching the end of the regulatory review process and expect a decision soon' with contingent P&L impactNCD reopening timing and scope uncertainty: Larry acknowledged 'it's impossible to know what they're going to do with operator requirements and facility requirements'Japan share recapture uncertainty: 'we are working really hard to regain some of the ground we've lost as new competitors have entered the market'

What to watch into next quarter

TAVR constant-currency growth holding above 7%. Q2 printed 7.8% cc, the strongest in over a year. The FY guide implies similar back-half pace; a step-down below 7% in Q3 would undercut the asymptomatic/NCD catalyst narrative.

TMTT quarterly revenue progression toward the $530-550M FY guide. Q2 ran at $134.5M GAAP; the implied 2H pace needs approximately $140-150M per quarter. Watch for sequential acceleration as Sapien M3 ramps in Europe and Evoque commercial expands.

JenaValve close in Q3 and disclosure of dilution/accretion mechanics. Management said "we remain hopeful" on Q3 close — slippage to Q4 would push the 2026 accretion thesis right.

Adjusted operating margin sustaining above 28%. Q2 hit 28.2% versus the FY 27-28% target band. Holding above 28% in 2H would presage outperformance against the +50-100bps 2026 commitment.

Sapien M3 US approval timing. Now expected 1H 2026 (no prior public timeline in our sourced materials). Any further slippage would be a credibility hit on the multi-modality portfolio claim.

FX vs. tariff trajectory. Management called out ~$30M of FY FX tailwind to sales at current rates; separately, tariffs were described as a headwind that has been "less than initially expected" with magnitude not disclosed. Watch for any disclosure that flips the net — stronger dollar erasing the FX tailwind, or incremental tariff exposure tied to subsequent trade actions.

Sources

  1. Edwards Lifesciences Q2 2025 earnings press release, filed via SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/ex-991q22025.htm
  2. Edwards Lifesciences Q2 2025 earnings call — prepared remarks and Q&A, attributable to CEO Bernard Zovighian, CFO Scott Ullem, TAVR/Surgical Group President Larry Wood, incoming TAVR leader Dan Lippis, and TMTT leader Devine Chopra.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.